Decoy Therapeutics (DCOY) Change in Accured Expenses (2015 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Change in Accured Expenses of -$617292.0 for Q1 2026, down 421.16% year-over-year from $192206.0 in Q1 2025, and down 14.05% quarter-over-quarter from -$541267.0 in Q4 2025.
Decoy Therapeutics (DCOY) Change in Accured Expenses (2015 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Change in Accured Expenses for 12 consecutive years, with -$617292.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 421.16% year-over-year to -$617292.0; the TTM figure through Mar 2026 stood at -$1.1 million (down 884.34% YoY), while the FY2025 annual figure was -$298903.0, down 450.2% from the prior year.
- Change in Accured Expenses slipped to -$617292.0 in Q1 2026 per DCOY's latest filing, from -$541267.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $498760.0 in Q3 2022 and bottomed at -$617292.0 in Q1 2026.
- Historically, Change in Accured Expenses has averaged -$65712.4 across 5 years, with a median of -$3436.0 in 2024.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses slumped 1386.68% — and 2025, when it soared 5693.89%.
- Decoy Therapeutics' Change in Accured Expenses stood at $28449.0 in 2022, then plunged by 1386.68% to -$366049.0 in 2023, then soared by 76.09% to -$87512.0 in 2024, then sank by 518.51% to -$541267.0 in 2025, then fell by 14.05% to -$617292.0 in 2026.
- Business Quant data shows DCOY's Change in Accured Expenses at -$617292.0 in Q1 2026, -$541267.0 in Q4 2025, and $4230.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - | -28,759.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28,759.00 |
| Jun 30, 2026 | -28,759.00 |
| Mar 31, 2026 | -617,292.00 |
| Mar 31, 2026 | -617,292.00 |
| Dec 31, 2025 | -541,267.00 |
| Dec 31, 2025 | -541,267.00 |
| Sep 30, 2025 | 4,230.00 |
| Sep 30, 2025 | 4,230.00 |
| Jun 30, 2025 | 45,928.00 |
| Jun 30, 2025 | 45,928.00 |
| Mar 31, 2025 | 192,206.00 |
| Mar 31, 2025 | 192,206.00 |
| Dec 31, 2024 | -87,512.00 |
| Dec 31, 2024 | -87,512.00 |
| Sep 30, 2024 | -95,487.00 |
| Sep 30, 2024 | -95,487.00 |
| Jun 30, 2024 | 132,109.00 |
| Jun 30, 2024 | 132,109.00 |
| Mar 31, 2024 | -3,436.00 |
| Mar 31, 2024 | -3,436.00 |